Sacubitril valsartan clinical trials
Includes 88 studies of Sacubitril valsartan sodium hydrate.
How each study uses sacubitril valsartan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sacubitril valsartan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 7 Jul 2015 · ENTRESTO · NDA 207620 (FDA, Drugs@FDA; as sacubitril valsartan sodium hydrate)
- European Union
- 19 Nov 2015 · Entresto · EMEA/H/C/004062 (EMA; as sacubitril valsartan sodium hydrate)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)
- 2
Studies by the year they started
91 studies that test it; most in 2016 (13)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 10 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 13 |
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 10 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 41 · Other 50
Novartis Pharmaceuticals (41) · Vanderbilt University Medical Center (3) · Brigham and Women's Hospital (2) · Mayo Clinic (2) · Duke University (2) · The Cleveland Clinic (2) · Ohio State University (1) · Saga University (1)
Often tested with
Tested in the same studies.
Valsartan (7) · Enalapril (3) · Sitagliptin (2) · Sacubitril (2) · Sertraline (1) · Clonazepam (1) · Alprazolam (1) · Metoprolol (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test sacubitril valsartan, phase 3 first.
- Jan 2027PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm AxisPhase 2/3 · University of Alabama at Birmingham
Studies
Open first, then newest update. How each study uses sacubitril valsartan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 91
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/ValsartanRecruitingPhase 1/2Virginia Commonwealth UniversityNCT05194111Written as Sacubitril-valsartan
- PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm AxisRecruitingPhase 2/3University of Alabama at BirminghamNCT04971720Written as Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
- Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)RecruitingPhase 4Silesian Centre for Heart DiseasesNCT05465031Written as Sacubitril-valsartan
- Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.RecruitingPhase 3University of Sao Paulo General HospitalNCT04853758Written as Sacubitril / Valsartan Oral Tablet [Entresto]
- Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection FractionRecruitingPhase 4Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in PoznańNCT05487261Written as Sacubitril-valsartan
- The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial InfarctionNot yet recruitingPhase 3West China HospitalNCT04912167Written as Sacubitril-Valsartan
- Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) StudyRecruitingPhase 4The Cleveland ClinicNCT04191681Written as Sacubitril-Valsartan
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3CompletedPhase 4Yale UniversityNCT04649229Written as LCZ 696
- The ENCHANTMENT HIV StudyCompletedPhase 2Massachusetts General HospitalNCT04153136Written as Sacubitril-Valsartan 49-51Mg Oral Tablet
- Effect of Sacubitril-Valsartan on Estimated Pulmonary Artery Systolic Pressure in Patients With Heart Failure With Reduced Ejection Fraction Heart FailureCompletedPhase 1Aswan UniversityNCT07814482Written as SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)
- Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection FractionWithdrawnPhase 4Brigham and Women's HospitalNCT06536309Written as Sacubitril-valsartan
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2CompletedPhase 4Vanderbilt University Medical CenterNCT04113109Written as LCZ 696
- Angiotensin-Neprilysin Inhibition in Hemodialysis InitiationCompletedPhase 2Brigham and Women's HospitalNCT05498181Written as Sacubitril-valsartan
- Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve RegurgitationCompletedPhase 4Ziekenhuis Oost-LimburgNCT05991284Written as Sacubitril-valsartan
- Sacubitril-valsartan in Patients With Heart Failure.CompletedNot applicableDamanhour UniversityNCT07341893Written as Sacubitril-valsartan
- Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial FibrillationCompletedPhase 4Shanghai Jiao Tong University School of MedicineNCT05528419Written as Sacubitril-valsartan
- PDD in Type 2 Diabetes w/wo Diastolic DysfunctionCompletedPhase 2Mayo ClinicNCT03744975Written as LCZ 696
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African AmericansActive, not recruitingPhase 4Ohio State UniversityNCT03938389Written as Sacubitril-Valsartan Tab 97-103 MG
- Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1TerminatedPhase 4Vanderbilt University Medical CenterNCT03738878Written as LCZ696
- Role of ARNi in Ventricular Remodeling in Hypertensive LVHCompletedPhase 2National Heart Centre SingaporeNCT03553810Written as Entresto
See all 91 studies that test sacubitril valsartan →
Given beside what is tested · 7 — sacubitril valsartan is usual care or a partner of the new treatment
- [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection FractionNot yet recruitingPhase 1Stony Brook UniversityNCT07856043Written as Sacubitril-Valsartan
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNot yet recruitingPhase 1Dr. Reddy's Laboratories (Thailand) LimitedNCT06193187Written as Entresto 50 mg
- [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion UptakeCompletedPhase 1/2Advanced Accelerator ApplicationsNCT03872778Written as LCZ696
- Initiation of ARNi and SGLT2i in Patients With HFrEFCompletedPhase 4Universidade do PortoNCT05989503Written as Sacubitril-valsartan
- 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid CancerCompletedEarly Phase 1University Hospital, Basel, SwitzerlandNCT03647657Written as Sacuitril
- Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.CompletedPhase 4Novartis PharmaceuticalsNCT02970669Written as sacubitril/valsartan (LCZ696)
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan TherapyCompletedPhase 4Cheng-Hsin General HospitalNCT04575675Written as Sacubitril-Valsartan
As the comparator · 4 — what is tested is compared with sacubitril valsartan
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNot yet recruitingPhase 1Viatris Inc.NCT06273254Written as Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNot yet recruitingPhase 1Viatris Inc.NCT06266988Written as Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)
- Bioequivalence Study of Valsatril Tablet Versus Entresto® Sacubitril/Valsartan 24/26 mg Tablet.CompletedPhase 1Center for Bioequivalence Studies and Clinical ResearchNCT07746908Written as Entresto®
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 MonotherapyCompletedPhase 3Novartis PharmaceuticalsNCT06236061Written as LCZ
What changed recently
From the registry's own updates since Oct 17, 2026.
Results posted1
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3Oct 27, 2026NCT04649229
Codes
What other systems call sacubitril valsartan · ClinicalTrials.gg INT015221
- UNII (FDA) 688RNR55GHSACUBITRIL VALSARTANOne source FDA
- NCI Thesaurus C222078Sacubitril ValsartanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 688RNR55GH | SACUBITRIL VALSARTAN | One source FDA |
| NCI Thesaurus | C222078 | Sacubitril Valsartan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.